KRAS and pancreatic neoplasm: Above, we found that ZNF154 hypermethylation in Illumina methylation array data (90.7%) was as frequent as KRAS mutations (90.7%) for the PAAD samples (Table 3), making pancreatic cancer an interesting case study for comparing the utility of the two markers for classifying samples from blood.